The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Acute Intermittent Porphyria Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
The global Acute Intermittent Porphyria Therapeutics market size is expected to reach US$ 56 million by 2029, growing at a CAGR of 1.8% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Intermittent Porphyria Therapeutics in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Acute Intermittent Porphyria Therapeutics market. 350mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 313mg segment is estimated at % CAGR for the next seven-year period.
Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Intermittent Porphyria Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Intermittent Porphyria Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Intermittent Porphyria Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Intermittent Porphyria Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Intermittent Porphyria Therapeutics covered in this report include Recordati Rare Diseases. etc.
The global Acute Intermittent Porphyria Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Recordati Rare Diseases
Global Acute Intermittent Porphyria Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Intermittent Porphyria Therapeutics market, Segment by Type:
350mg
313mg
Global Acute Intermittent Porphyria Therapeutics market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acute Intermittent Porphyria Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
The global Acute Intermittent Porphyria Therapeutics market size is expected to reach US$ 56 million by 2029, growing at a CAGR of 1.8% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Intermittent Porphyria Therapeutics in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Acute Intermittent Porphyria Therapeutics market. 350mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 313mg segment is estimated at % CAGR for the next seven-year period.
Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Intermittent Porphyria Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Intermittent Porphyria Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Intermittent Porphyria Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Intermittent Porphyria Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Intermittent Porphyria Therapeutics covered in this report include Recordati Rare Diseases. etc.
The global Acute Intermittent Porphyria Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Recordati Rare Diseases
Global Acute Intermittent Porphyria Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Intermittent Porphyria Therapeutics market, Segment by Type:
350mg
313mg
Global Acute Intermittent Porphyria Therapeutics market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acute Intermittent Porphyria Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Acute Intermittent Porphyria Therapeutics
1.1 Acute Intermittent Porphyria Therapeutics Market Overview
1.1.1 Acute Intermittent Porphyria Therapeutics Product Scope
1.1.2 Acute Intermittent Porphyria Therapeutics Market Status and Outlook
1.2 Global Acute Intermittent Porphyria Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Acute Intermittent Porphyria Therapeutics Market Size by Region (2018-2029)
1.4 Global Acute Intermittent Porphyria Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Acute Intermittent Porphyria Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Acute Intermittent Porphyria Therapeutics Market Size (2018-2029)
1.6.1 North America Acute Intermittent Porphyria Therapeutics Market Size (2018-2029)
1.6.2 Europe Acute Intermittent Porphyria Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Acute Intermittent Porphyria Therapeutics Market Size (2018-2029)
1.6.4 Latin America Acute Intermittent Porphyria Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Acute Intermittent Porphyria Therapeutics Market Size (2018-2029)
2 Acute Intermittent Porphyria Therapeutics Market by Type
2.1 Introduction
2.1.1 350mg
2.1.2 313mg
2.2 Global Acute Intermittent Porphyria Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Acute Intermittent Porphyria Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Acute Intermittent Porphyria Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Type (2018-2029)
3 Acute Intermittent Porphyria Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Pharmacy
3.2 Global Acute Intermittent Porphyria Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Acute Intermittent Porphyria Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Acute Intermittent Porphyria Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Acute Intermittent Porphyria Therapeutics Revenue Breakdown by Application (2018-2029)
4 Acute Intermittent Porphyria Therapeutics Competition Analysis by Players
4.1 Global Acute Intermittent Porphyria Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acute Intermittent Porphyria Therapeutics as of 2022)
4.3 Date of Key Players Enter into Acute Intermittent Porphyria Therapeutics Market
4.4 Global Top Players Acute Intermittent Porphyria Therapeutics Headquarters and Area Served
4.5 Key Players Acute Intermittent Porphyria Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Acute Intermittent Porphyria Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Recordati Rare Diseases
5.1.1 Recordati Rare Diseases Profile
5.1.2 Recordati Rare Diseases Main Business
5.1.3 Recordati Rare Diseases Acute Intermittent Porphyria Therapeutics Products, Services and Solutions
5.1.4 Recordati Rare Diseases Acute Intermittent Porphyria Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Recordati Rare Diseases Recent Developments
6 North America
6.1 North America Acute Intermittent Porphyria Therapeutics Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Acute Intermittent Porphyria Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Acute Intermittent Porphyria Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Acute Intermittent Porphyria Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Acute Intermittent Porphyria Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Acute Intermittent Porphyria Therapeutics Market Dynamics
11.1 Acute Intermittent Porphyria Therapeutics Industry Trends
11.2 Acute Intermittent Porphyria Therapeutics Market Drivers
11.3 Acute Intermittent Porphyria Therapeutics Market Challenges
11.4 Acute Intermittent Porphyria Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
